Evidence map›Paper›PMID 40832286›Full record

ArticlebioRxiv : the preprint server for biology2025

A clade 2.3.4.4b H5N1 virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins.

Eduard Puente-Massaguer, Thales Galdino Andrade, Michael J Scherm, Kirill Vasilev, Hassanein Abozeid, Alesandra J Rodriguez, Josh Yueh, Disha Bhavsar, John D Campbell, Dong Yu and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Eduard Puente-MassaguerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Thales Galdino AndradeDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Michael J SchermDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kirill VasilevDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hassanein AbozeidDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Alesandra J RodriguezDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Josh YuehDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Disha BhavsarDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
John D CampbellDynavax Technologies Corporation, Emeryville, CA, USA.
Dong YuDynavax Technologies Corporation, Emeryville, CA, USA.
Richard J WebbyDepartment of Host Microbe Interactions, St Jude Children's Research Hospital, Memphis, TN, USA.
Yoshihiro KawaokaDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Gabriele NeumannDepartment of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Julianna HanDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7153-3769
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
New York City Virus Hunters - A Community Science InitiativeR25GM150146 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Florian Krammer, Christine Marizzi · 2023 to 2026
$1.1M
NIAID NIH HHS 75N93019C00051NIGMS NIH HHS R25 GM150146
6 · The paper itself

Abstract

The continuous evolution and widespread dissemination of highly pathogenic avian influenza (HPAI) H5N1 viruses, particularly clade 2.3.4.4b, pose critical challenges to global pandemic preparedness. In this study, we assessed a low-dose inactivated split virus vaccine derived from clade 2.3.4.4b H5N1, formulated with an Alum/CpG adjuvant, using a preclinical mouse model. This vaccine induced potent humoral and cellular immune responses, generating high titers of cross-reactive antibodies targeting both hemagglutinin (HA) and neuraminidase (NA) glycoproteins across homologous and heterologous H5 clades. The Alum/CpG adjuvant enabled significant antigen dose-sparing while promoting a balanced Th1/Th2 immune profile. Functional analyses demonstrated strong virus neutralization, neuraminidase inhibition, and potent antibody-dependent cellular cytotoxicity activity. Additionally, the vaccine elicited robust antigen-specific CD4

Identifiers

PMID40832286
PMCPMC12363970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.